X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ASTRAZENECA PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE ASTRAZENECA PHARMA CADILA HEALTHCARE/
ASTRAZENECA PHARMA
 
P/E (TTM) x 13.7 91.9 14.9% View Chart
P/BV x 2.9 20.3 14.2% View Chart
Dividend Yield % 1.4 0.0 -  

Financials

 CADILA HEALTHCARE   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
ASTRAZENECA PHARMA
Mar-18
CADILA HEALTHCARE/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs5581,278 43.7%   
Low Rs362883 41.0%   
Sales per share (Unadj.) Rs116.3228.4 50.9%  
Earnings per share (Unadj.) Rs17.910.4 172.4%  
Cash flow per share (Unadj.) Rs23.116.3 142.3%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs85.498.8 86.5%  
Shares outstanding (eoy) m1,023.7425.00 4,095.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.04.7 83.6%   
Avg P/E ratio x25.7104.2 24.7%  
P/CF ratio (eoy) x19.966.4 29.9%  
Price / Book Value ratio x5.410.9 49.2%  
Dividend payout %19.60-   
Avg Mkt Cap Rs m470,66427,008 1,742.7%   
No. of employees `00011.81.4 871.6%   
Total wages/salary Rs m18,5451,535 1,207.9%   
Avg. sales/employee Rs Th10,072.74,210.9 239.2%   
Avg. wages/employee Rs Th1,569.11,132.2 138.6%   
Avg. net profit/employee Rs Th1,547.7191.1 810.0%   
INCOME DATA
Net Sales Rs m119,0495,710 2,084.9%  
Other income Rs m1,132123 924.1%   
Total revenues Rs m120,1815,833 2,060.5%   
Gross profit Rs m28,475463 6,151.4%  
Depreciation Rs m5,388147 3,655.4%   
Interest Rs m9110-   
Profit before tax Rs m23,308438 5,321.5%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,644179 3,154.8%   
Profit after tax Rs m18,292259 7,059.8%  
Gross profit margin %23.98.1 295.0%  
Effective tax rate %24.240.8 59.3%   
Net profit margin %15.44.5 338.6%  
BALANCE SHEET DATA
Current assets Rs m82,0053,209 2,555.3%   
Current liabilities Rs m60,7202,070 2,934.0%   
Net working cap to sales %17.920.0 89.6%  
Current ratio x1.41.6 87.1%  
Inventory Days Days7372 101.1%  
Debtors Days Days9835 281.5%  
Net fixed assets Rs m83,703790 10,591.3%   
Share capital Rs m1,02450 2,048.0%   
"Free" reserves Rs m86,4212,419 3,572.1%   
Net worth Rs m87,4452,469 3,541.3%   
Long term debt Rs m25,5510-   
Total assets Rs m180,6534,605 3,922.6%  
Interest coverage x26.6NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.71.2 53.2%   
Return on assets %10.65.6 188.9%  
Return on equity %20.910.5 199.4%  
Return on capital %22.017.7 124.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,683300 14,249.0%   
Fx outflow Rs m11,2422,015 557.9%   
Net fx Rs m31,441-1,715 -1,832.9%   
CASH FLOW
From Operations Rs m9,19388 10,458.5%  
From Investments Rs m-9,737-94 10,402.8%  
From Financial Activity Rs m515NA-  
Net Cashflow Rs m-29-6 508.8%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.3 0.3 2,766.7%  
FIIs % 5.9 15.7 37.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 9.1 120.9%  
Shareholders   44,069 12,856 342.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 234 Points Higher; Healthcare and Realty Stocks Rally(Closing)

After opening the day on a flat note, Indian share markets witnessed buying interest during closing hours and ended higher.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today(Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jul 16, 2019 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - DIVIS LABORATORIES COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS